Sleep apnoea linked to elevated lipids

CVD risk factors including hyperlipidaema need to be carefully managed in OSA

Patients with obstructive sleep apnoea (OSA) are also likely to have dyslipidaemia, European research suggests.

snoring man

OSA is an independent predictor of higher total cholesterol and LDL, elevated triglycerides and lower HDL, according to the cross-sectional analysis of more than 8000 sleep centre patients, published in Respirology.

Total cholesterol concentrations also gradually rise with increasing OSA severity, they found. 

"Our data clearly suggest that sleep apnoea may have a negative impact on lipid levels, which may in part explain the association between sleep apnoea and increased risk for cardiovascular disease," said lead researcher Dr Ludger Grote, from Sweden’s Gothenburg University.

“Patients with sleep apnoea, therefore, need careful management of all cardiovascular risk factors, including hyperlipidaema.”

Nearly 8600 study participants, mean age 50, were enrolled in the wider European Sleep Apnoea Database cohort study and were recruited from 24 sleep centres across 18 countries.

None of the participants had been previously diagnosed with hyperlipidaemia and were not taking lipid=lowering medication.

The link between OSA and dyslipidaemia was assessed across several measures of sleep apnoea, including the apnoea-hypopnoea index, oxygen desaturation index, and mean and lowest oxygen saturation. 

Geography influenced results, with patients from northern Europe recording the highest total cholesterol levels, followed by central, southern, eastern and western regions.

“Potential explanations for these regional differences include previously identified genetic and dietary factors,” the researchers said.

But they found morbid obesity was a confounder, with these patients recording lower total cholesterol levels than overweight and obese patients.

This suggests BMI alone doesn’t predict the influence of obesity on lipid levels, with previous research showing abdominal obesity was linked to dyslipidaemia, the researchers wrote.

“As a clinical implication of our findings, clinicians should be aware of the association between OSA and dyslipidaemia. Indeed comorbid dyslipidaemia, a well-recognised cardiovascular risk factor, is highly likely to affect the overall cardiovascular consequences and prognosis in OSA,” they said. 

The impact of OSA treatment on lipid levels still needed to be evaluated, the researchers concluded.


Read the full study here.